∗Neurological Institute, Movement Disorders Unit, Tel Aviv Medical Center

†Department of Neurology, Sackler Faculty of Medicine

‡Sagol School of Neuroscience

§Department of Epidemiology, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University

∥Maccabi Healthcare Services, Tel Aviv, Israel.

Address correspondence and reprint requests to Achinoam Faust-Socher, MD, Tel Aviv Medical Center, Movement Disorders Unit, 6th Weizman St, Tel-Aviv, Israel; E-mail: [email protected]

Conflicts of Interest and Source of Funding: T.G. reports advisory board membership with honoraria to her and to her Institution AbbVie Israel, Neuroderm, Ltd, and Allergan and research support from Phonetica, Ltd, Israeli Innovation Authority, Sagol School of Neuroscience (Brain Boost) and Parkinson's Foundation. N.G. reports that he is a consultant for Neuroderm, Intec Pharma, Teva, Genzyme-Sanofi, Biogen, Lysosomal Therapeutics, Denali, Cellanis, GaitBetter, Vibrant, and Sionara; that he holds shares or options in Lysosomal Therapeutics, Cellanis, GaitBetter, and Vibrant; that he has received royalties from Lysosomal Therapeutics; that he received honorarium from UCB, Teva, Novartis, AbbVie, Genzyme-Sanofie, Neuroderm, Bial, Shire, and MDS; that he has chaired the DSMBs for Teva and Pharma2B; that he is a Principal Investigator on a Center Grant given by Biogen to TLVMC; that he has submitted a patent application on the use of body-fixed sensors for assessing PD symptoms, the intellectual property rights for which are held by the Tel Aviv Medical Center; and that he received grants from Teva, Biogen, LTI, ISF, EU, National Institutes of Health, MJFF, Parkinson Foundation, and Pfizer. The other authors have no conflicts of interest to declare.

Funding was received for this work from any of the following organizations: National Institutes of Health, Wellcome Trust, and Howard Hughes Medical Institute.